Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Endometrial Cancer, Papillary Serous Endometrial Carcinoma, Uterine Serous Carcinoma, Endometrial Carcinoma, Cancer of the Endometrium
Interventions
Niraparib
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
New Brunswick, New Jersey • Newark, New Jersey • Bay Shore, New York + 3 more
Conditions
Endometrial Carcinoma
Interventions
Biospecimen Collection, Low-Dose Aspirin, Patient Observation, Questionnaire Administration, Ultrasound Imaging
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Completed No phase listed Observational Accepts healthy volunteers

Hormonal Effects on the Uterus and Endometrium

NCT00001454
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 43 Years · Female only
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Infertility of Uterine Origin
Interventions
Platelet Rich Plasma Intrauterine infusion, Normal saline Intrauterine infusion
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Lung Cancer, Melanoma, Non-Hodgkin's Lymphoma, Uterine Cancer, CORPUS UTERI,ENDOMETRIUM, LUNG, OVARY
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Papillary Serous Carcinoma of the Endometrium

NCT00515073
Conditions
Endometrial Cancer
Interventions
Paclitaxel, Pelvic Radiation, Dexamethasone, Cimetidine, Diphenhydramine
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen, Diet, Genetics and Endometrial Cancer

NCT00587886
Conditions
Cancer, Endometrial Cancer, Ovarian Cancer, Corpus Uteri, Endometrium
Interventions
Questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
1,315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Active, not recruiting No phase listed Observational

Tempus Priority Study: A Pan-tumor Observational Study

NCT05179824
Conditions
Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Conditions
Endometrial Cancer, Cancer of the Endometrium
Interventions
TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF

NCT01202643
Conditions
Infertility, Female
Interventions
G-CSF, Saline
Drug
Lead sponsor
Center for Human Reproduction
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Accepts healthy volunteers

Endometrial Biopsy in Infertile Patients

NCT00064935
Conditions
Infertility
Interventions
Endometrial biopsy
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
25 Years to 39 Years · Female only
Enrollment
880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
8
States / cities
Birmingham, Alabama • Denver, Colorado • Detroit, Michigan + 5 more
Conditions
Endometrial Cancer
Interventions
Fluorescence-guided sentinel lymph node detection
Procedure
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Issaquah, Washington • Seattle, Washington
Conditions
Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
Interventions
BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Infertility
Interventions
Acupuncture, Electro-Acupuncture
Procedure
Lead sponsor
National University of Health Sciences
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Lombard, Illinois
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms
Interventions
PF-07260437, B7-H4 IHC
Drug · Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 6 more
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Conditions
Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Female, Uterine Neoplasms, Endometrial Neoplasms, Cancer of Endometrium, Endometrial Cancer, Cancer of the Endometrium, Endometrium Cancer, Neoplasms, Endometrial
Interventions
pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Endometrial Endometrioid Adenocarcinoma
Interventions
Abemaciclib, Letrozole, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Chicago, Illinois
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01949
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Nashville, Tennessee + 1 more
Conditions
Endometrial Cancer, Endometrial Neoplasms
Interventions
XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Newport Beach, California • Orlando, Florida • Augusta, Georgia + 7 more